Shots:

• The P-IV IXORA-R study involves assessing of Taltz (160 mg at wk 0- followed by 80 mg at wks. 2- 4- 6- 8- 10- and 12- then 80 mg- q4w) vs Tremfya (SC- 100 mg) in 1-027 patients with moderate to severe plaque psoriasis evaluating efficacy- safety for 24 wks.
• The study met 1EPs @12 wks. demonstrating superiority in the proportion of patients achieving complete skin clearance by PASI 100. Additionally- @12wks. the study met all 2EPs including superiority in patients achieving PASI 75 @2wks.- PASI 90 @4 & 8Wks.- PASI 100 @4 & 8wks.- and sPGA 0/50 @wks. 12 &1 respectively. Safety profile of Taltz was consistent with no new safety signals observed
•  Taltz is a mAb binds to interleukin 17A (IL-17A) cytokine and further inhibits its interaction with IL-17 receptor. Additionally- Lilly plans to share remaining @2EPs achieving PASI 100 at 24 weeks in 2020 

Click here to read full press release/ article

Ref: Eli Lilly | Image: Eli Lilly